Impact of thalassemia major on patients and their families

被引：47

作者：

Caro, JJ

Ward, A

Greene, TC

Huybrechts, K

Arana, A

Wait, S

Eleftheriou, A

机构：

[1] Caro Res, Concord, MA USA

[2] McGill Univ, Royal Victoria Hosp, Div Gen Internal Med, Montreal, PQ H3A 1A1, Canada

[3] Novartis Farmaceut SA, Barcelona, Spain

[4] Novartis Pharma AG, Basel, Switzerland

[5] Thalassemia Int Fdn, Nicosia, Cyprus

来源：

ACTA HAEMATOLOGICA | 2002年 / 107卷 / 03期

关键词：

thalassemia major; desferrioxamine; quality of life; burden of illness; treatment; complications; international survey;

D O I：

10.1159/000057633

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs, and the patient's physical and social well-being. Methods: From October 1999 to May 2000 a survey of patients with thalassemia major was conducted in ten countries: Cyprus., Egypt, Greece, Hong Kong, India, Iran, Italy, Jordan, Taiwan, and the United States. Results: 1,888 questionnaires (65%) were returned. The responses suggest that nowadays patients begin blood transfusions, and most use desferrioxamine (84.8%), but iron-related complications, including life-threatening ones such as heart disease, are still common. Conclusions: There remains a need to improve the management of thalassemia, as many patients with iron-related complications experience physical and social limitations. Copyright (C) 2002 S. Karger AG, Basel.

引用

页码：150 / 157

页数：8

共 15 条

[1]

BASRAN R, 1994, BLOOD S, V94, pA261

[2] Survival and disease complications in thalassemia major [J].

Borgna-Pignatti, C ;

Rugolotto, S ;

De Stefano, P ;

Piga, A ;

Di Gregorio, F ;

Gamberini, MR ;

Sabato, V ;

Melevendi, C ;

Cappellini, MD ;

Verlato, G .

COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 :227-231

[3]

CAO A, 1997, MANAGMENT PROTOCOL T

[4]

Ehlers K H, 1980, Ann N Y Acad Sci, V344, P397

[5]

Gamberini MR, 1998, J PEDIATR ENDOCR MET, V11, P867

[6] THE EFFECT OF SUBCUTANEOUS DEFEROXAMINE ON THE CARDIAC PROFILE OF THALASSEMIA MAJOR - A 5-YEAR STUDY [J].

GIARDINA, PJV ;

EHLERS, KH ;

ENGLE, MA ;

GRADY, RW ;

HILGARTNER, MW .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1985, 445 (JUN) :282-292

[7]

HUSSAIN MAM, 1976, LANCET, V2, P1278

[8]

Loukopoulos D, 1996, SEMIN HEMATOL, V33, P76

[9]

Low LCK, 1997, J PEDIATR ENDOCR MET, V10, P175

[10]

MODEL B, 1994, GUIDELINES CONTROL H

← 1 2 →